Robertson, John F R <br/><br/>
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.  [electronic resource] 

 -  Breast cancer research and treatment  Nov 2012 
 - 503-11 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-012-2192-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anastrozole<br/>Antineoplastic Agents, Hormonal--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Estradiol--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Fulvestrant<br/>Humans<br/>Neoplasm Staging<br/>Nitriles--administration & dosage<br/>Treatment Outcome<br/>Triazoles--administration & dosage